Sarepta Therapeutics Stock
€120.25
Your prediction
Financial data and news for Sarepta
sharewise wants to provide you with the best news and tools for Sarepta, so we directly link to the best financial data sources.
Financials
News
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA)
Why Sarepta Therapeutics Stock Is Soaring Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were soaring 10.4% higher as of 10:58 a.m. ET on Friday. The big gain came after the biopharmaceutical company announced that the U.S. Food and Drug
2 Magnificent Growth Stocks to Buy With $500
Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
In biotech, it's often difficult to tell whether bad news for one company will also be bad news for a competitor, or vice versa. Between using different approaches to therapy development, working
Could Sarepta Therapeutics Become the Next Vertex Pharmaceuticals?
Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta
3 Things About Sarepta Therapeutics Every Smart Investor Knows
Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
The word "revolutionary" sometimes gets thrown around a lot, but it certainly applies to Sarepta Therapeutics (NASDAQ: SRPT). This midcap biotech company has developed several treatments for
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a
My Take: 4 Strong Growth Stocks to Buy This Week
Are you looking for new growth stocks for your portfolio? The idea was compelling a week ago when the market was roaring higher. Now, with fresh headwinds blowing, not so much.
Just bear in mind
3 Monster Stocks in the Making
Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.
Which smaller stocks
Is Sarepta Therapeutics Stock a Bad-News Buy?
Investing in biotech stocks is risky. And one of the more volatile ones of late is Sarepta Therapeutics (NASDAQ: SRPT). Shares of the company crashed last week after it released results from phase 3
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Biotech companies working on gene therapies have made significant strides lately, but many of them remain relatively risky stocks. Still, gene therapies have the potential to help transform medicine
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
Sarepta Therapeutics (NASDAQ: SRPT)Q3 2023 Earnings CallNov 01, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Why Sarepta Therapeutics Stock Is Crashing Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were crashing 43.6% lower as of 11:10 a.m. ET on Tuesday. The huge sell-off came after the company announced top-line results from its phase 3 Embark
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
PepGen Inc. (NASDAQ: PEPG) is a clinical-stage biotech focused on developing therapies for rare neuromuscular and neurological genetic diseases like Duchenne muscular dystrophy (DMD). PepGen
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. This medical sector company specializes in